Re:Ingestible Anti-Microbial Formula Kills Candida Species, etc...

[Guest guest]

Interesting that they claim it (and their other products) have a 100% kill rate.

But candida

is a beneficial fungus or bacteria(?) that is present in everyone's gut. It's

just when it takes

over and creates and imbalance and/or moves out of the gut that it causes major

problems. I suppose it would naturally come back to a lesser degree after

treatment.

Then they say they have products for Anthrax, for the Avian Flu, etc -- but what

year will

these actually end up on the market? My guess -- 2008, 2009?

But thanks Bob for posting this!

d

> From: " tigerpaw2c " <tigerpaw2c@y...>

> Date: Tue, 03 Jan 2006 22:44:46 -0000

> Subject: [] Ingestible Anti-Microbial Formula Kills Candida

Species

>

> January 03, 2006 10:15 AM US Eastern Timezone

>

> Knock-out Technologies' Ingestible Anti-Microbial Formula Kills

> Candida Species in Independent Laboratory Testing; Human Clinical

> Studies to Commence

>

> http://home.businesswire.com/portal/site/google/index.jsp?

> ndmViewId=news_view & newsId=20060103005394 & newsLang=en

>

> SCOTTSDALE, Ariz.--(BUSINESS WIRE)--Jan. 3, 2006-- Bowker,

> president/CEO of Knock-Out Technologies Ltd., a wholly owned

> subsidiary of eFoodSafety.com Inc. (OTCBB: EFSF), announced today

> that its newly developed ingestible food-grade, anti-microbial

> formula has shown a 100% kill of Candida Species, a major health

> concern, in independent laboratory testing.

>

>

> When our body defenses are compromised (immunosuppressed), fungal

> infections become opportunistic and Candida is the most common of

> these fungal infections. Candida infections have dramatically

> increased in the hospital setting, notably the intensive care unit

> and surgical intensive care unit, with associated morbidity and

> mortality. The incidence in hospitals increased 500% from 1980 to

> 1989. Chronically ill patients, such as cancer patients undergoing

> chemotherapy, steroid dependent transplant patients, HIV positive

> patients, COPD patients, burn victims and patients with prosthetic

> implants (valves, joints) are identified as patients at high risk to

> contract Candida. There is also a high incidence among patients with

> indwelling catheters and surgical wounds, as well as patients

> receiving antibiotics or gastric acid-reducing treatments and also

> patients who suffer from severe trauma, obesity, diabetes, and

> alcohol or drug abuse. Developing new preventative and treatment

> strategies has surfaced as a major priority in the medical

> community. Currently available treatment and prophylaxis is not

> without risk. A major adverse effect of current therapy is renal

> toxicity.

>

> Hospital, medical and surgical services now routinely give a

> prophylactic treatment for their highest risk patients in special

> care units. The $40,000 increase in the cost of critically ill

> patients can be attributed to Candida infections. Candida Species in

> the bloodstream has the highest mortality rate of all pathogens

> isolated.

>

> Ross-Gruden, president/CEO of eFoodSafety.com Inc., stated

> that due to the favorable laboratory results, we are scheduled to

> begin human clinical studies with our treatment for Candida mid-

> February 2006. " We feel strongly that we as a company have an

> obligation to improve outcomes in the treatment of patients with the

> Candida infection and provide prophylaxis against future Candida

> infections without the major side effects of currently available

> treatments. Knock-Out Technologies continues to remain on the

> cutting edge of revolutionary new products and ideas with which we

> can improve our lives and do so without causing toxicity to humans, "

> added Ross-Gruden.

>

> About eFoodSafety.com Inc.

>

> eFoodSafety.com Inc. is dedicated to improving food and health

> conditions around the world through its innovative technologies. The

> company's Knock-Out Technologies Ltd. subsidiary has developed an

> environmentally safe sporicidal product formulated entirely of food-

> grade components that eradicates anthrax and a germicidal product

> that kills six major bacteria: E-coli, Listeria, Pseudomonas,

> Salmonella, Staphylococcus and Streptococcus, Avian Influenza and

> Black Mold. The sporicidal product has completed its final efficacy

> laboratory study requisite for EPA registration. In the study, it

> eradicated both Clostridium Sporogenes and Bacillus Subtilis with

> 100% efficacy on both hard and porous surfaces. The company's

> MedElite Inc. subsidiary distributes clinically proven products to

> physicians who then prescribe the products for their patients. It is

> the exclusive U.S. and worldwide distributor of the Talsyn-

> CI/bid Scar Cream that has been clinically proven to facilitate and

> improve the appearance, redness and strength of scars

> (www.talsyn.com). The company is also a distributor for Cinnergen

> , a non-prescription liquid whole food nutritional supplement

> that promotes healthy glucose metabolism (www.cinnergen.com), and

> most recently became a distributor for Trimmendous, a weight

> loss formula focusing on the body's 24-hour metabolic processes.

>

> Safe Harbor Forward-Looking Statements

>

> Statements contained in this release that are not strictly

> historical are " forward-looking " statements within the meaning of

> Section 27A of the Securities Act of 1933 as amended, and Section

> 21E of the Securities Exchange Act of 1934, as amended. The forward-

> looking statements are made based on information available as of the

> date hereof, and the company assumes no obligation to update such

> forward-looking statements. Editors and investors are cautioned that

> such forward-looking statements invoke risk and uncertainties and

> the company's actual results may differ from these forward-looking

> statements. Such risks and uncertainties include but are not limited

> to demand for the company's products and services, our ability to

> continue to develop markets, general economic conditions, our

> ability to secure additional financing for the company and other

> factors that may be more fully described in reports to shareholders

> and periodic filings with the Securities and Exchange Commission.

>

> Contacts

>

>

> Redwood Consultants, LLC

> Jens Dalsgaard, 415-884-0348

>

>

>

>

>

>

>

>

>

> FAIR USE NOTICE:

>

>

>

>

>

>

[Guest guest]

>

> Interesting that they claim it (and their other products) have a

100% kill rate. But candida

> is a beneficial fungus or bacteria(?) that is present in everyone's

gut. It's just when it takes

> over and creates and imbalance and/or moves out of the gut that it

causes major

> problems. I suppose it would naturally come back to a lesser

degree after treatment.

I had the same thought. Does anyone know for sure if candida is

necessary in our guts? I know it is there naturally. I have always

wondered why a tube could not be stuck down our throats or somehow

and repopulate our bacteria with what is natural? Does it not pay

enough money?

I had my fourth colon irrigation today and I have seen parasites and

large pieces of dark fecal matter which I was told has been blocking

the intestines for some time. He also gives wheatgrass enema's which

he claims is good. I am surprised this guy is in Oklahoma! He grew up

here but worked in Dallas.

Any warnings on colon irrigations?

Bob

Bob

[Guest guest]

If it sounds too good to be true, it peobably is too good to be true.

It will be interesting to follow their progress.

Barb

To:

> > From: " tigerpaw2c " <tigerpaw2c@y...>

> > Date: Tue, 03 Jan 2006 22:44:46 -0000

> > Subject: [] Ingestible Anti-Microbial Formula Kills

Candida Species

> >

> > January 03, 2006 10:15 AM US Eastern Timezone

> >

> > Knock-out Technologies' Ingestible Anti-Microbial Formula Kills

> > Candida Species in Independent Laboratory Testing; Human Clinical

> > Studies to Commence

> >

> > http://home.businesswire.com/portal/site/google/index.jsp?

> > ndmViewId=news_view & newsId=20060103005394 & newsLang=en

> >

> > SCOTTSDALE, Ariz.--(BUSINESS WIRE)--Jan. 3, 2006-- Bowker,

> > president/CEO of Knock-Out Technologies Ltd., a wholly owned

> > subsidiary of eFoodSafety.com Inc. (OTCBB: EFSF), announced today

> > that its newly developed ingestible food-grade, anti-microbial

> > formula has shown a 100% kill of Candida Species, a major health

> > concern, in independent laboratory testing.

> >

> >

> > When our body defenses are compromised (immunosuppressed), fungal

> > infections become opportunistic and Candida is the most common of

> > these fungal infections. Candida infections have dramatically

> > increased in the hospital setting, notably the intensive care

unit

> > and surgical intensive care unit, with associated morbidity and

> > mortality. The incidence in hospitals increased 500% from 1980 to

> > 1989. Chronically ill patients, such as cancer patients

undergoing

> > chemotherapy, steroid dependent transplant patients, HIV positive

> > patients, COPD patients, burn victims and patients with

prosthetic

> > implants (valves, joints) are identified as patients at high risk

to

> > contract Candida. There is also a high incidence among patients

with

> > indwelling catheters and surgical wounds, as well as patients

> > receiving antibiotics or gastric acid-reducing treatments and

also

> > patients who suffer from severe trauma, obesity, diabetes, and

> > alcohol or drug abuse. Developing new preventative and treatment

> > strategies has surfaced as a major priority in the medical

> > community. Currently available treatment and prophylaxis is not

> > without risk. A major adverse effect of current therapy is renal

> > toxicity.

> >

> > Hospital, medical and surgical services now routinely give a

> > prophylactic treatment for their highest risk patients in special

> > care units. The $40,000 increase in the cost of critically ill

> > patients can be attributed to Candida infections. Candida Species

in

> > the bloodstream has the highest mortality rate of all pathogens

> > isolated.

> >

> > Ross-Gruden, president/CEO of eFoodSafety.com Inc.,

stated

> > that due to the favorable laboratory results, we are scheduled to

> > begin human clinical studies with our treatment for Candida mid-

> > February 2006. " We feel strongly that we as a company have an

> > obligation to improve outcomes in the treatment of patients with

the

> > Candida infection and provide prophylaxis against future Candida

> > infections without the major side effects of currently available

> > treatments. Knock-Out Technologies continues to remain on the

> > cutting edge of revolutionary new products and ideas with which

we

> > can improve our lives and do so without causing toxicity to

humans, "

> > added Ross-Gruden.

> >

> > About eFoodSafety.com Inc.

> >

> > eFoodSafety.com Inc. is dedicated to improving food and health

> > conditions around the world through its innovative technologies.

The

> > company's Knock-Out Technologies Ltd. subsidiary has developed an

> > environmentally safe sporicidal product formulated entirely of

food-

> > grade components that eradicates anthrax and a germicidal product

> > that kills six major bacteria: E-coli, Listeria, Pseudomonas,

> > Salmonella, Staphylococcus and Streptococcus, Avian Influenza and

> > Black Mold. The sporicidal product has completed its final

efficacy

> > laboratory study requisite for EPA registration. In the study, it

> > eradicated both Clostridium Sporogenes and Bacillus Subtilis with

> > 100% efficacy on both hard and porous surfaces. The company's

> > MedElite Inc. subsidiary distributes clinically proven products

to

> > physicians who then prescribe the products for their patients. It

is

> > the exclusive U.S. and worldwide distributor of the Talsyn-

> > CI/bid Scar Cream that has been clinically proven to facilitate

and

> > improve the appearance, redness and strength of scars

> > (www.talsyn.com). The company is also a distributor for Cinnergen

> > , a non-prescription liquid whole food nutritional supplement

> > that promotes healthy glucose metabolism (www.cinnergen.com), and

> > most recently became a distributor for Trimmendous, a weight

> > loss formula focusing on the body's 24-hour metabolic processes.

> >

> > Safe Harbor Forward-Looking Statements

> >

> > Statements contained in this release that are not strictly

> > historical are " forward-looking " statements within the meaning of

> > Section 27A of the Securities Act of 1933 as amended, and Section

> > 21E of the Securities Exchange Act of 1934, as amended. The

forward-

> > looking statements are made based on information available as of

the

> > date hereof, and the company assumes no obligation to update such

> > forward-looking statements. Editors and investors are cautioned

that

> > such forward-looking statements invoke risk and uncertainties and

> > the company's actual results may differ from these forward-

looking

> > statements. Such risks and uncertainties include but are not

limited

> > to demand for the company's products and services, our ability to

> > continue to develop markets, general economic conditions, our

> > ability to secure additional financing for the company and other

> > factors that may be more fully described in reports to

shareholders

> > and periodic filings with the Securities and Exchange Commission.

> >

> > Contacts

> >

> >

> > Redwood Consultants, LLC

> > Jens Dalsgaard, 415-884-0348

> >

> >

> >

> >

> >

> >

> >

> >

> >

> > FAIR USE NOTICE:

> >

> >

> >

> >

> >

> >